# GCC Anti VEGF Market > GCC Anti-VEGF Market Research Report By Product (Eylea, Lucentis, Beovu) and By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.56% - **2024:** $ 389.76 Million - **2025:** $ 407.53 Million - **2035:** $ 636.6 Million - **Key Players:** Regeneron Pharmaceuticals (US), Roche (CH), Novartis (CH), Bayer (DE), Pfizer (US), Amgen (US), Eli Lilly and Company (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) **Report ID:** MRFR/HC/50411-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-anti-vegf-market-52169 --- ## Market Summary ## **GCC Anti-VEGF Market Overview** ### As per MRFR analysis, the GCC Anti-VEGF Market Size was estimated at 1.05 (USD Billion) in 2023.The GCC Anti-VEGF Market Industry is expected to grow from 1.09(USD Billion) in 2024 to 1.86 (USD Billion) by 2035. The GCC Anti-VEGF Market CAGR (growth rate) is expected to be around 4.981% during the forecast period (2025 - 2035). ### **Key GCC Anti-VEGF Market Trends Highlighted** The GCC Anti-VEGF market is undergoing significant trends that are influenced by a variety of factors. The increasing prevalence of retinal disorders, particularly age-related macular degeneration (AMD) and diabetic retinopathy, is a significant driver. It is becoming more prevalent in the GCC region. Healthcare providers are increasingly emphasizing innovative therapies that utilize Anti-VEGF agents in response to the increasing demand for effective treatment options in countries such as the UAE and Saudi Arabia, where populations are ageing. Furthermore, the market is being influenced by government initiatives that are designed to improve the accessibility of advanced treatment options and improve the quality of healthcare infrastructure. The incorporation of advanced medical technologies and the promotion of healthcare investments are being promoted by initiatives such as Saudi Vision 2030 and the UAE Vision 2021. Pharmaceutical companies are afforded numerous opportunities to introduce new anti-VEGF therapies in order to meet the changing requirements of patients, as a result of this supportive environment. There has been a recent trend towards personalized medicine, which emphasizes the treatment of patients according to their unique health profiles. This trend is resulting in the development of Anti-VEGF treatments that are more specifically tailored to the needs of the GCC, thereby ensuring that the efficacy and safety of the therapies are optimized. Additionally, there is a growing trend of collaborations between global pharmaceutical companies and local healthcare providers, which facilitates the supply of anti-VEGF products and enhances clinical outcomes. Therefore, the GCC Anti-VEGF market is on the brink of expansion, propelled by a convergence of evolving patient-centric approaches, government support, and healthcare advancements. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **GCC Anti-VEGF Market Drivers** ### **Increasing Prevalence of Eye Diseases** The GCC Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Market Industry is witnessing significant growth driven by the increasing prevalence of eye diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. According to regional health authorities, there has been a reported increase in the number of individuals affected by these conditions, with studies indicating that the prevalence of [diabetic retinopathy](../../../reports/diabetic-retinopathy-market-5792) alone is around 20% among the diabetic population in the Gulf Cooperation Council (GCC) states. As the population in the GCC ages, the incidence of such diseases is expected to rise. For instance, the Health Authority of Abu Dhabi has highlighted that the elderly population is projected to reach 25% by 2030, which will directly contribute to a higher demand for anti-VEGF therapies. This increasing patient pool is critical for the growth and prospects of the GCC Anti-VEGF Market, attracting investments and innovations from leading pharmaceutical companies operating in the region. ### **Technological Advancements in Treatment Options** Ongoing technological advancements in the development and delivery of Anti-VEGF treatments are significantly enhancing the efficacy and accessibility of therapy options in the GCC Anti-VEGF Market Industry. With the introduction of more targeted therapies and refined injection techniques, the treatment outcomes have seen notable improvement. For instance, a study by the Saudi Ophthalmology Society has asserted that new drug formulations are leading to better patient compliance and lower incidence of side effects. Moreover, increasing investment in Research and Development (R&D) by major healthcare players, such as Novartis and Regeneron, continuously drives the market forward. This focus on innovative treatment modalities aligns with the broader GCC health initiatives aimed at enhancing healthcare delivery and improving patient outcomes in the region. ### **Growing Awareness and Screening Initiatives** The GCC Anti-VEGF Market Industry is also benefiting from growing awareness around eye health and the importance of early screening for eye diseases. Governments in the GCC, such as Qatar and the United Arab Emirates, have launched national health campaigns aimed at educating the public about the risks associated with untreated eye diseases. For instance, the Qatar Ministry of Public Health reported a significant increase in public participation in screening initiatives, with around 15,000 citizens participating in eye screening programs in 2022 alone. Such initiatives are essential in facilitating early diagnosis, thus promoting timely intervention with anti-VEGF treatments. This heightened awareness is expected to lead to an increase in healthcare expenditure on eye health, thereby fueling growth in the GCC Anti-VEGF Market. ## **GCC Anti-VEGF Market Segment Insights** ### **Anti-VEGF Market Product Insights** The GCC Anti-VEGF Market is experiencing notable developments, particularly within the Product segment, which encompasses various treatment options designed to address neovascular conditions such as age-related macular degeneration and diabetic retinopathy. This market is characterized by significant competition among leading products, including Eylea, Lucentis, and Beovu, each known for its effectiveness in reducing vision loss caused by retinal diseases. Eylea has gained a favorable position in many healthcare settings due to its dosing schedule, which can lead to improved patient adherence compared to alternatives. Lucentis, while well-established, continues to play an essential role owing to its longstanding acceptance and clinical efficacy, making it a preferred choice among physicians treating retinal disorders. Beovu represents a newer entrant in the market, offering innovative treatment options that appeal to both healthcare providers and patients looking for advanced therapies with potentially fewer injections required over time. As the population of the GCC region ages, the demand for effective treatment options for vision-threatening diseases is likely to increase. Government initiatives in the GCC, aimed at enhancing healthcare access and improving medical facilities, bolster the growth of the Anti-VEGF market by facilitating better distribution and availability of these important products. Furthermore, an increase in healthcare spending and rising awareness of eye health among the public contribute to the market's growth trajectory.  Each of these products brings unique benefits, catering to different patient needs and preferences, which fosters further segmentation within the market. Additionally, ongoing Research and Development are likely to yield new formulations and delivery mechanisms, enhancing the effectiveness of existing treatments and expanding options for patients in the region.What stands out in this Product segment is the continuous innovation and improvement driven by competitive pressures. The presence of multiple effective choices empowers patients and doctors to select therapies that best fit individual treatment plans.  Moreover, as the healthcare infrastructure transforms in the GCC, including better support for chronic condition management, the significance of these products within the Anti-VEGF market will grow. With a focus on improving outcomes and accessibility, the GCC Anti-VEGF Market is poised for sustained growth, reflecting broader trends in healthcare development and an emphasis on patient-centered care initiatives. As this market continues to evolve, it is crucial to monitor how these products adapt to changing healthcare landscapes and regulatory environments, ensuring that they meet the rising expectations for both efficacy and patient experience. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Anti-VEGF Market Disease Insights** The GCC Anti-VEGF Market, particularly within the Disease segment, has shown a robust growth trajectory, driven by the increasing prevalence of vision-related disorders such as macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. The rising incidence of diabetes in the GCC region has significantly elevated cases of diabetic retinopathy, making it a focal point for treatment advances. Macular edema continues to dominate the landscape due to its debilitating effect on eyesight, necessitating effective therapeutic interventions.Furthermore, retinal vein occlusion represents a significant concern as it links directly with increasing rates of cardiovascular diseases prevalent in the GCC. Age-related macular degeneration underscores the effect of population aging, urging healthcare systems to adopt innovative treatment solutions. These conditions collectively contribute to the high demand for Anti-VEGF therapies in the GCC, reflecting not only an urgent healthcare need but also presenting opportunities for industry advancements and research in drug development, thus boosting the overall GCC Anti-VEGF Market dynamics.With supportive healthcare policies and increasing awareness about early detection and treatment, the Disease segment is poised for notable progress in the coming years. ## **GCC Anti-VEGF Market Key Players and Competitive Insights** The GCC Anti-VEGF Market is characterized by a dynamic and rapidly evolving competitive landscape that caters to the growing demand for ocular therapies, particularly for age-related macular degeneration and diabetic retinopathy treatments. As healthcare systems in the Gulf Cooperation Council region increasingly focus on improving patient outcomes, anti-VEGF medications have emerged as critical components of ophthalmic care. The competition within this market is influenced by several factors, including the increasing prevalence of retinal diseases, advancements in treatment administration techniques, healthcare policies, and collaborative efforts between governments and pharmaceutical companies to enhance patient access to innovative therapies. Key players in the market are striving to develop novel formulations and delivery systems while leveraging their established supply chains and relationships with healthcare providers to capture significant market share. Hoya Corporation is recognized for its robust presence within the GCC Anti-VEGF Market due to its focus on innovative eyecare solutions and optical products. The company's strengths lie in its advanced research and development capabilities that allow for the creation of effective and high-quality anti-VEGF treatments tailored to the specific needs of the region. Hoya Corporation's reputation for precision in manufacturing and commitment to improving patient quality of life has garnered trust among healthcare providers and patients alike. Moreover, the company benefits from its extensive distribution networks and strategic partnerships within the GCC, which facilitate the timely delivery of its products across various healthcare institutions, thereby enhancing its competitive advantage in the region. Regeneron Pharmaceuticals holds a prominent position in the GCC Anti-VEGF Market, particularly with its flagship product targeting various retinal diseases. This company's strengths are rooted in its relentless focus on innovation, which has led to a strong pipeline of therapies aimed at addressing unmet medical needs in the region. Regeneron's strategic approach includes collaborations with local healthcare providers and institutions to ensure its treatments are widely available and well-integrated into existing healthcare frameworks. Additionally, the company has pursued mergers and acquisitions that enhance its research capabilities and broaden its therapeutic offerings, thereby solidifying its market presence. With a commitment to leveraging cutting-edge technology and maintaining high standards of clinical efficacy, Regeneron Pharmaceuticals continues to play a pivotal role in advancing anti-VEGF therapeutic options in the GCC, ultimately contributing to improved patient outcomes and driving market growth. ### **Key Companies in the GCC Anti-VEGF Market Include** ### **GCC Anti-VEGF Market Industry Developments** Recent developments in the GCC Anti-VEGF market have shown robust activity, particularly among major pharmaceutical players. Hoya Corporation and Regeneron Pharmaceuticals are focusing on expanding their product portfolios within the region, capitalizing on the increasing prevalence of retinal diseases. Santen Pharmaceutical and Amgen are also set to enhance their offerings as the GCC healthcare sector experiences substantial growth, attributed partly to government investments in healthcare infrastructure. In July 2023, Novartis announced a significant collaboration with Alcon to co-develop innovative therapies, aligning with market demands. Bayer's recent partnership with Roche aims at leveraging their research capabilities, enhancing their market presence. Additionally, there has been a notable increase in market valuation, with reports indicating a compound annual growth rate of over 8% for Anti-VEGF treatments from 2021 to 2023, driven by rising incidences of diabetic retinopathy and age-related macular degeneration in the region. In the past two years, in November 2022, Pfizer made headlines with the acquisition of a niche biotech firm focused on novel anti-VEGF molecules, indicating a strategic expansion within the GCC market. The momentum in mergers and collaborations continues to reshape the competitive landscape in the region. ## **GCC Anti-VEGF Market Segmentation Insights** ### **Anti-VEGF Market Product Outlook** ### **Anti-VEGF Market Disease Outlook** ## Market Drivers ### Rising Healthcare Expenditure The rising healthcare expenditure in the GCC region is a significant driver for the anti vegf market. As countries in the region allocate more resources to healthcare, there is an increasing focus on advanced treatment options for chronic diseases, including retinal disorders. Reports indicate that healthcare spending in the GCC is projected to reach $100 billion by 2025, with a substantial portion directed towards innovative therapies. This trend suggests that healthcare providers are more likely to invest in anti vegf treatments, which are essential for managing conditions like AMD and diabetic retinopathy. Furthermore, the willingness of patients to seek treatment for eye disorders is likely to increase as healthcare systems improve, thereby further stimulating the anti vegf market. ### Growing Awareness and Education Growing awareness and education regarding eye health in the GCC region are crucial factors influencing the anti vegf market. Public health campaigns aimed at educating the population about the risks and symptoms of retinal diseases are becoming more prevalent. This increased awareness is likely to lead to earlier diagnosis and treatment, which is essential for conditions that require anti-VEGF therapies. Additionally, healthcare professionals are receiving enhanced training on the latest treatment options, further promoting the use of anti vegf agents. As patients become more informed about their treatment options, the demand for effective therapies is expected to rise. Consequently, this trend may contribute to the overall growth of the anti vegf market in the region. ### Government Initiatives and Funding Government initiatives and funding aimed at improving healthcare infrastructure in the GCC are likely to play a pivotal role in the anti vegf market. Increased investment in healthcare systems, particularly in ophthalmology, is expected to enhance access to anti vegf treatments. For example, several GCC countries have launched national health programs focused on eye health, which include screening and treatment for retinal diseases. This proactive approach may lead to a higher diagnosis rate and subsequent treatment of conditions requiring anti-VEGF therapies. Additionally, public-private partnerships in the healthcare sector could facilitate the development and distribution of innovative anti vegf products. As a result, the anti vegf market may experience accelerated growth due to these supportive government measures. ### Increasing Prevalence of Eye Disorders The rising prevalence of eye disorders in the GCC region is a crucial driver for the anti vegf market. Conditions such as age-related macular degeneration (AMD) and diabetic retinopathy are becoming more common, leading to a higher demand for effective treatments. Recent estimates suggest that the incidence of AMD in the GCC could reach 1.5 million cases by 2025. This growing patient population necessitates the availability of anti-VEGF therapies, which are essential for managing these conditions. As healthcare systems in the GCC continue to evolve, the focus on improving patient outcomes through advanced treatment options is likely to bolster the anti vegf market. Furthermore, increased awareness and early diagnosis of these disorders may contribute to a surge in treatment uptake, thereby enhancing the overall market landscape. ### Technological Advancements in Treatment Technological advancements in the field of ophthalmology are significantly impacting the anti vegf market. Innovations such as sustained-release drug delivery systems and combination therapies are enhancing the efficacy and convenience of treatments. For instance, the introduction of long-acting anti vegf agents could potentially reduce the frequency of injections required for patients, improving adherence to treatment regimens. The GCC region is witnessing a surge in research and development activities aimed at creating more effective anti-VEGF therapies. This focus on innovation is expected to drive market growth, as healthcare providers seek to offer the latest treatment options to their patients. Moreover, the integration of digital health technologies, such as telemedicine, may facilitate better patient management and follow-up, further supporting the anti vegf market. ## Future Outlook The [Anti VEGF Market](https://www.marketresearchfuture.com/reports/anti-vegf-market-21963) is projected to grow at a 4.56% CAGR from 2025 to 2035, driven by increasing prevalence of retinal diseases and advancements in treatment options. **New opportunities:** - Development of combination therapies to enhance efficacy and patient compliance. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Investment in localized manufacturing to reduce costs and improve supply chain efficiency. By 2035, the anti-VEGF market is expected to achieve substantial growth, driven by innovative strategies and increased demand. ## Segment Insights ### By Product: Eylea (Largest) vs. Beovu (Fastest-Growing) In the GCC anti vegf market, Eylea holds the largest market share among the product segment values, outperforming its competitors, Lucentis and Beovu. While Lucentis has maintained a significant presence, its market position is being increasingly challenged by the rise of Beovu, which is gaining traction among healthcare providers. The competitive dynamics set the stage for evolving preferences in treatment options, leveraging patient outcomes and clinician experiences to influence market share distribution. Growth trends indicate a robust trajectory for the anti vegf products, driven by increases in age-related macular degeneration cases and diabetic retinopathy. Innovative delivery methods and improved efficacy profiles are paramount in shaping the market landscape. Additionally, the increasing adoption of Beovu, attributed to its dosing convenience and efficacy, positions it as a strong candidate for future growth. Awareness campaigns and educational initiatives further fuel this growth, enhancing treatment accessibility and shifting prescriber preferences in favor of newer options. Eylea (Dominant) vs. Beovu (Emerging) Eylea stands as the dominant force in the GCC anti vegf market, known for its strong efficacy in treating various retinal diseases, particularly age-related macular degeneration. Its established reputation among ophthalmologists has resulted in a loyal patient base and consistent prescription rates. In contrast, Beovu, labeled as an emerging product, is quickly gaining popularity due to its innovative formulation that allows for less frequent dosing. This significant convenience is appealing to patients and clinicians alike, enhancing adherence to treatment. Both products serve distinct patient needs and preferences, with Eylea focusing on proven performance while Beovu paves its growth path through innovation and convenience. ### By Disease: Age-Related Macular Degeneration (Largest) vs. Diabetic Retinopathy (Fastest-Growing) In the GCC anti vegf market, the segment distribution shows that Age-Related Macular Degeneration (AMD) holds the largest share, reflecting its prevalence and significant healthcare focus. Following closely, Diabetic Retinopathy is emerging as a crucial segment, driven by the increasing incidence of diabetes and the need for effective treatment options. Macular Edema and Retinal Vein Occlusion, while present, represent smaller portions of the market, indicating a more niche positioning within the overall framework. Growth trends reveal that the GCC anti vegf market is experiencing a noteworthy momentum, particularly in the Diabetic Retinopathy space, which is identified as the fastest-growing segment. Factors contributing to this growth include rising diabetic patient populations, enhanced awareness, and advancements in anti-VEGF therapies. The ongoing research and development efforts, coupled with healthcare policy improvements, are expected to further drive the demand for anti-VEGF treatments, making it a dynamic area for market participants to watch. Age-Related Macular Degeneration: Dominant vs. Diabetic Retinopathy: Emerging In the GCC anti vegf market, Age-Related Macular Degeneration (AMD) stands out as the dominant segment, owing to the aging population and a growing emphasis on eye health. AMD treatments are well-established, forming a significant component of therapeutic protocols in the region. On the other hand, Diabetic Retinopathy is marked as an emerging segment, bolstered by the increasing prevalence of diabetes and related eye complications. Both segments attract considerable investment, with AMD benefiting from established protocols while Diabetic Retinopathy experiences rapid development driven by innovative therapies tailored to the diabetic demographic. This dynamic illustrates a critical shift in focus, with AMD being a staple while Diabetic Retinopathy propels forward as the segment to watch. ## Competitive Benchmarking The anti-VEGF market is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and the growing demand for effective therapies. Key players such as Regeneron Pharmaceuticals (US), Roche (CH), and Novartis (CH) are at the forefront, leveraging their robust portfolios and innovative capabilities. Regeneron Pharmaceuticals (US) focuses on expanding its product offerings and enhancing its R&D capabilities, while Roche (CH) emphasizes strategic partnerships to bolster its market presence. Novartis (CH) is actively pursuing digital transformation initiatives to optimize patient engagement and streamline operations. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set the pace for innovation and establish benchmarks for quality and efficacy in anti-VEGF therapies. In October Regeneron Pharmaceuticals (US) announced a collaboration with a leading biotechnology firm to develop next-generation anti-VEGF therapies. This strategic move is likely to enhance Regeneron's R&D capabilities and accelerate the introduction of innovative treatments, thereby reinforcing its competitive edge in the market. The collaboration underscores the importance of partnerships in driving innovation and expanding therapeutic options for patients. In September Roche (CH) launched a new digital platform aimed at improving patient access to anti-VEGF treatments. This initiative is significant as it not only enhances patient engagement but also streamlines the treatment process, potentially leading to better health outcomes. Roche's focus on digital solutions reflects a broader trend in the industry towards integrating technology into healthcare delivery. In August Novartis (CH) expanded its manufacturing capabilities in the GCC region, aiming to meet the rising demand for anti-VEGF therapies. This expansion is strategically important as it positions Novartis to respond more effectively to local market needs while reducing lead times for product availability. Such moves indicate a shift towards localized production, which may enhance supply chain reliability and operational efficiency. As of November current trends in the anti-VEGF market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies position themselves in the market, emphasizing the importance of delivering high-quality, effective therapies that meet the evolving needs of patients. ## Recent News & Developments Recent developments in the GCC Anti-VEGF market have shown robust activity, particularly among major pharmaceutical players. Hoya Corporation and Regeneron Pharmaceuticals are focusing on expanding their product portfolios within the region, capitalizing on the increasing prevalence of retinal diseases. Santen Pharmaceutical and Amgen are also set to enhance their offerings as the GCC healthcare sector experiences substantial growth, attributed partly to government investments in healthcare infrastructure. In July 2023, Novartis announced a significant collaboration with Alcon to co-develop innovative therapies, aligning with market demands. Bayer's recent partnership with Roche aims at leveraging their research capabilities, enhancing their market presence. Additionally, there has been a notable increase in market valuation, with reports indicating a compound annual growth rate of over 8% for Anti-VEGF treatments from 2021 to 2023, driven by rising incidences of diabetic retinopathy and age-related macular degeneration in the region. In the past two years, in November 2022, Pfizer made headlines with the acquisition of a niche biotech firm focused on novel anti-VEGF molecules, indicating a strategic expansion within the GCC market. The momentum in mergers and collaborations continues to reshape the competitive landscape in the region. ## Report Scope | MARKET SIZE 2024 | 389.76(USD Million) | | --- | --- | | MARKET SIZE 2025 | 407.53(USD Million) | | MARKET SIZE 2035 | 636.6(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.56% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Roche (CH), Novartis (CH), Bayer (DE), Pfizer (US), Amgen (US), Eli Lilly and Company (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) | | Segments Covered | Product, Disease | | Key Market Opportunities | Emerging therapies targeting retinal diseases create growth potential in the anti vegf market. | | Key Market Dynamics | Rising demand for innovative anti-VEGF therapies driven by increasing prevalence of retinal diseases in the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What was the overall market valuation of the GCC anti VEGF market in 2024?** A: The overall market valuation was $389.76 Million in 2024. **Q: What is the projected market valuation for the GCC anti VEGF market by 2035?** A: The projected valuation for 2035 is $636.6 Million. **Q: What is the expected CAGR for the GCC anti VEGF market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period is 4.56%. **Q: Which product segment had the highest valuation in 2024?** A: In 2024, Eylea had the highest valuation at $250.0 Million. **Q: What is the valuation range for Lucentis in the GCC anti VEGF market?** A: The valuation range for Lucentis is between $120.0 Million and $200.0 Million. **Q: Which disease segment is projected to have the highest valuation by 2035?** A: Age-Related Macular Degeneration is projected to have the highest valuation by 2035, reaching $246.6 Million. **Q: Who are the key players in the GCC anti VEGF market?** A: Key players include Regeneron Pharmaceuticals, Roche, Novartis, Bayer, Pfizer, Amgen, Eli Lilly and Company, Santen Pharmaceutical, and Horizon Therapeutics. **Q: What was the valuation for the Diabetic Retinopathy segment in 2024?** A: The valuation for the Diabetic Retinopathy segment was $90.0 Million in 2024. **Q: What is the valuation range for Beovu in the GCC anti VEGF market?** A: The valuation range for Beovu is between $119.76 Million and $186.6 Million. **Q: How does the market valuation in 2035 compare to that in 2024?** A: The market valuation in 2035 is expected to increase by $246.84 Million compared to 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-anti-vegf-market-52169*